The online version of this article (doi:10.1186/s12885-017-3247-z) contains supplementary material, which is available to authorized users.
The standard treatment for esthesioneuroblastoma, a rare malignant nasal vault neoplasm, is not established.
We retrospectively assessed the clinicopathological features, prognostic factors and treatment methods for 187 patients with esthesioneuroblastoma treated in China between 1981 and 2015. Overall survival (OS) and disease-free survival (DFS) were evaluated using the Kaplan-Meier method and log-rank tests.
Twenty-three (12.3%), 48 (25.7%) and 113 (60.4%) patients had Kadish stage A, B and C esthesioneuroblastoma; 3 (1.6%) had unknown stage. Overall, 117 (62.6%) patients received surgery and combined radiotherapy with or without chemotherapy; 35 (18.7%) received radiotherapy with or without chemotherapy; 32 (17.1%) received surgery alone; and 3 (1.6%) received palliative treatment. Three-year OS and DFS for the entire cohort were 66.7% and 57.5%, respectively. Three-year OS for stage A, B and C were 91.3%, 91.2% and 49.5% (P < 0.0001). Three-year OS was 16.7% and 66.7% for patients with and without distant metastasis (P < 0.0001). Surgery and combined radiotherapy with or without chemotherapy led to better OS and DFS than other treatment modes (both P < 0.0001). Univariate and multivariate analysis showed distant metastasis (hazard ratio [HR] = 2.162, 95% confidence interval [CI] = 1.145, 4.082, P = 0.017) and not receiving a combined modality treatment (HR = 2.391, 95% CI = 1.356, 4.218, P = 0.003) were independent prognostic factors for poor OS and DFS.
This study indicates surgery and combined radiotherapy may currently be the optimal treatment for esthesioneuroblastoma.
Broich G, Pagliari A, Ottaviani F. Esthesioneuroblastoma: a general review of the cases published since the discovery of the tumour in 1924. Anticancer Res. 1997;17:2683–706. PubMed
Svane-Knudsen V, Jorgensen KE, Hansen O, Lindgren A, Marker P. Cancer of the nasal cavity and paranasal sinuses: a series of 115 patients. Rhinology. 1998;36:12–4. PubMed
Bragg TM, Scianna J, Kassam A. Clinicopathological review: esthesioneuroblastoma. Neurosurgery. 2009;64 :764-770. 770.
Lapierre A, Selmaji I, Samlali H, Brahmi T, Yossi S. Esthesioneuroblastoma: A single institution's experience and general literature review. Cancer Radiother. 2016;20(8):783–89.
Tajudeen BA, Adappa ND, Kuan EC. Smell preservation following endoscopic unilateral resection of esthesioneuroblastoma: a multi-institutional experience. Int Forum Allergy Rhinol. 2016;6(10):1047–50.
Hwang SK, Paek SH, Kim DG, Jeon YK, Chi JG, Jung HW. Olfactory neuroblastomas: survival rate and prognostic factor. J Neuro-Oncol. 2002;59(3):217–26. CrossRef
- Optimal treatment and prognostic factors for esthesioneuroblastoma: retrospective analysis of 187 Chinese patients
- BioMed Central
Neu im Fachgebiet Onkologie
Mail Icon II